N30 Pharmaceuticals, a Colorado-based clinical stage biopharmaceutical company, has treated the first patient in Phase Ib/IIa trial of N6022 in cystic fibrosis (CF) patients with two copies of the F508del-CFTR mutation.

The multicentre, double-blind study is designed to evaluate ascending doses of N6022 in patients with the most common and serious form of CF.

The study is being conducted in collaboration with the Cystic Fibrosis Foundation’s Therapeutics Development Network (TDN), and the first patient was dosed at National Jewish Health in Denver.

"The primary objective of the randomised, placebo-controlled study is to assess the safety of repeat doses of N6022."

N30 Pharma president and chief executive officer Dr Charles Scoggin said; "We are indebted to the cystic fibrosis clinicians and nurses who have given us such valuable advice, to the members of the TDN who have been instrumental in getting this first trial started, and to the patients who will be volunteering for participation."

The primary objective of the randomised, placebo-controlled study is to assess the safety of repeat doses of N6022.

The evaluation of N6022 serum levels, lung function and other markers of disease activity in CF are the secondary and exploratory objectives of the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

N6022 is the first candidate in N30 Pharma’s new class of drugs targeting conservation of endogenous, signalling molecule, S-nitrosoglutathione (GSNO), believed to decrease in CF patients.

The drugs are said to restore GSNO levels by inhibiting S-nitrosoglutathione reductase, the enzyme that breaks down GSNO.

N6022 has previously been studied for the treatment of asthma.